About this trial
This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic therapy. The study includes analysis of the tumor immune microenvironment (TIME), circulating immune and inflammatory molecules, immune cell subsets, and circulating tumor DNA (ctDNA). The goal is to identify biomarkers associated with spontaneous or treatment-induced tumor regression and to evaluate potential correlations with specific ß-catenin mutations.
Eligibility criteria
Qualifiers
Patients with primary sporadic desmoid-type fibromatosis with measurable disease under active surveillance
Patients with primary sporadic desmoid-type fibromatosis with measurable disease receiving systemic treatment.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead sponsor
Campus Biomedico - Roma
Collaborator
Candiolo Cancer Institute - IRCCS
Collaborator
Azienda Ospedaliero-Universitaria Careggi
Collaborator
Azienda USL Toscana Centro
Collaborator
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborator
Erasmus University Rotterdam
Collaborator
Istituto Oncologico Veneto IRCCS
Collaborator